<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083183</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005632</org_study_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>NCI-2019-05727</secondary_id>
    <secondary_id>9524</secondary_id>
    <nct_id>NCT04083183</nct_id>
  </id_info>
  <brief_title>Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases</brief_title>
  <official_title>Targeted Astatine-211-Labeled BC8-B10 Monoclonal Antibody as Reduced Intensity Conditioning for Nonmalignant Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose of total body irradiation with astatine-211
      BC8-B10 monoclonal antibody for the treatment of patients with nonmalignant diseases
      undergoing hematopoietic cell transplant. Radiation therapy uses high energy gamma rays to
      kill cancer cells and shrink tumors. Astatine-211-labeled BC8-B10 monoclonal antibody is a
      monoclonal antibody, called anti-CD45 monoclonal antibody BC8-B10, linked to a
      radioactive/toxic agent called astatine 211. Anti-CD45 monoclonal antibody BC8-B10 is
      attached to CD45 antigen positive cancer cells in a targeted way and delivers astatine 211 to
      kill them. Giving astatine-211 BC8-B10 monoclonal antibody and total-body irradiation before
      a donor stem cell transplant may help stop the growth of cells in the bone marrow, including
      normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's
      immune system from rejecting the donor's stem cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

      Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 intravenously (IV) on
      any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1
      hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2.
      Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5,
      patients also receive mycophenolate mofetil orally (PO) or IV thrice daily every 8 hours up
      to day 35 if no GVHD present and sirolimus PO daily until day 365.

      After completion of study treatment, patients are followed up at 1 and 2 years and then
      periodically for up to 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2020</start_date>
  <completion_date type="Anticipated">January 9, 2028</completion_date>
  <primary_completion_date type="Anticipated">January 9, 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft rejection (arm A)</measure>
    <time_frame>Up to 5 years post-transplant</time_frame>
    <description>Defined as establishment of &lt; 5% donor chimerism of CD3+ T cells and &lt;5% donor chimerism of CD33+ myeloid cells at day 80‐100 after hematopoietic cell transplant (HCT) following an human leukocyte antigen (HLA)‐matched related or unrelated graft or an unrelated graft with a single HLA‐class 1 allele mismatch or DQB1 antigen or allele mismatch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft rejection (arm B)</measure>
    <time_frame>Up to 5 years post-transplant</time_frame>
    <description>Defined as establishment of &lt; 5% donor chimerism of CD3+ T cells and &lt; 5% donor chimerism of CD33+ myeloid cells at day 80‐100 after HCT following an HLA‐haploidentical related donor or an unrelated donor mismatched for a single HLA‐class 1 antigen or a single HLA‐DRB1 allele.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute graft versus host disease (GVHD)</measure>
    <time_frame>At day 100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of chronic GVHD</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor chimerism</measure>
    <time_frame>At day 28, day 84, and 1 year post-transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive astatine At 211 anti-CD45 monoclonal antibody BC8-B10 IV on any day between days -10 and -7, fludarabine IV on days -6 to -2, cyclophosphamide IV over 1 hour on days -6 to -5 and 3 to 4, and thymoglobulin IV over 4-6 hours on days -4 to -2. Patients undergo TBI on day -1 and hematopoietic cell transplant on day 0. Beginning day 5, patients also receive mycophenolate mofetil PO or IV thrice daily every 8 hours up to day 35 if no GVHD present and sirolimus PO daily until day 365.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Astatine 211-Labeled Anti-CD45 Monoclonal Antibody BC8-B10</other_name>
    <other_name>Astatine At 211 MAb BC8-B10</other_name>
    <other_name>At 211 Anti-CD45 Monoclonal Antibody BC8-B10</other_name>
    <other_name>At 211 MAb BC8-B10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>118218</other_name>
    <other_name>2-Fluoro-9-beta-arabinofuranosyladenine</other_name>
    <other_name>2-Fluorovidarabine</other_name>
    <other_name>21679-14-1</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine</other_name>
    <other_name>9-Beta-D-arabinofuranosyl-2-fluoroadenine</other_name>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lapine T-Lymphocyte Immune Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Anti-thymocyte Globulin Rabbit</other_name>
    <other_name>Grafalon</other_name>
    <other_name>Rabbit Anti-Human Thymocyte Globulin (RATG)</other_name>
    <other_name>Rabbit Anti-Thymocyte Globulin</other_name>
    <other_name>Rabbit Antithymocyte Globulin</other_name>
    <other_name>Rabbit ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo hematopoietic cell transplantation</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO or IV</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
    <other_name>115007-34-6</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (astatine 211,fludarabine,cyclophosphamide,TBI,HCT)</arm_group_label>
    <other_name>226080</other_name>
    <other_name>RAPA</other_name>
    <other_name>Rapamune</other_name>
    <other_name>Rapamycin</other_name>
    <other_name>SILA 9268A</other_name>
    <other_name>WY-090217</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nonmalignant disease treatable by allogeneic hematopoietic cell transplantation (HCT).
             Patients with a nonmalignant disease that is not clearly defined must be approved by
             the principal investigator (PI)

          -  Lansky play performance score or Karnofsky score &gt;= 70

          -  DONOR INCLUSION

          -  HLA matched related donor that is genotypically or phenotypically identical for HLA‐A,
             ‐B, ‐C, ‐DRB1, ‐DQB1. Phenotypic identity must be confirmed by high‐resolution typing.
             Sibling donors are preferred over other relationships

          -  Unrelated donor.

               -  Matched for HLA‐A, ‐B, ‐C, ‐DRB1, and DQB1 by high‐resolution typing; OR

               -  Mismatched for a single HLA‐class 1 allele or HLA‐DQB1 antigen or allele by
                  high‐resolution typing.

        Note: A donor homozygous for one allele only at HLA‐A, B, C, DRB1, or DQB1 is allowed (1
        antigen mismatch for graft versus host disease [GVHD], 0 antigen mismatch for
        graft‐rejection). In the case of a recipient who is homozygous at one locus, the mismatch
        is not allowed to be at that locus (0 antigen mismatch for GVHD, 1 antigen mismatch for
        graft‐rejection)

          -  HLA haploidentical donor. There must be one shared HLA‐haplotype based on inheritance.
             The noninherited haplotype is allowed to be mismatched at any or all of these loci:
             HLA‐A, B, C, DRB1 or DQB1.

          -  Donor selection guideline recommendations: in the case where there are multiple donor
             options, donors should be selected based on the following priority numbered below:

               -  Related donor genotypically HLA‐matched

               -  Related donor phenotypically HLA‐matched

               -  Unrelated donor HLA‐matched

               -  Unrelated donor with single allele level mismatch at class 1 (HLA‐A, ‐B, or ‐C).
                  For example, HLA‐A02:01 versus HLA‐A 02:02

               -  Unrelated donor with single allele level mismatch at DQB1

               -  HLA‐haploidentical donor Note: We require that the donor testing be performed by
                  a United States Clinical Laboratory Improvement Amendment (CLIA) approved
                  laboratory. In the very rare case where the donor testing is not able to be
                  performed in a CLIA approved laboratory, or there is confirmatory testing that
                  needs to be performed, or for any donor identified from Europe and at risk for
                  Creutzfeldt‐Jakob Disease (CJD), we note this on the donor screening form and
                  require that the unrelated donor medical director or the attending physician
                  approves the use of the donor HPC‐A product under urgent medical need

        Exclusion Criteria:

          -  Patients with Fanconi Anemia

          -  Impaired cardiac function as evidenced by ejection fraction &lt; 35% (or, if unable to
             obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac insufficiency
             requiring treatment or symptomatic coronary artery disease. Patients with a shortening
             fraction of &lt; 26% may be enrolled if approved by a cardiologist. In addition, patients
             with poorly controlled hypertension on multiple anti‐hypertensive medications,
             symptomatic coronary artery disease, or patients on cardiac medications for
             antiarrhythmic or inotropic effects are excluded

          -  Impaired pulmonary function as evidenced by carbon monoxide diffusing capability test
             (DLCO) &lt; 35% of predicted or receiving supplemental continuous oxygen. In addition, if
             patients are unable to perform pulmonary function tests, then O2 saturation &lt; 92% on
             room air

          -  Impaired renal function as evidenced by estimated creatinine clearance less than 50
             ml/min or serum creatinine &gt; 2 x upper normal limit or dialysis‐dependent. Serum
             creatinine value must be within 28 days prior to start of conditioning

             * The creatinine clearance may be estimated by the Cockcroft‐Gault formula

          -  Impaired liver function as evidenced by abnormal hepatic function defined as a total
             bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) &gt; 2
             times the upper limit of normal. In addition, patients with the following liver
             abnormalities are excluded: fulminant liver failure, cirrhosis of the liver with
             evidence of portal hypertension, alcoholic hepatitis, esophageal varices, hepatic
             encephalopathy, uncorrectable hepatic synthetic dysfunction as evidenced by
             prolongation of the prothrombin time, ascites related to portal hypertension,
             bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis, or
             symptomatic biliary disease

          -  An uncontrolled infection requiring deferral of conditioning as recommended by an
             infectious disease specialist. A viral upper respiratory tract infection does not
             constitute an uncontrolled infection in this context

          -  Patients who are known to be positive for HIV (human immunodeficiency virus)

          -  Women of childbearing potential who are pregnant or breast‐feeding

          -  Fertile men or women unwilling to use contraceptive techniques during and for 12
             months following treatment

          -  Allergy to murine‐based monoclonal antibodies

          -  Known contraindication to radiotherapy

          -  DONOR EXCLUSION

          -  Donors are excluded when preexisting immunoreactivity is identified that would
             jeopardize donor hematopoietic cell engraftment. The recommended procedure for
             patients with 10 of 10 HLA allele level (phenotypic) match is to obtain panel reactive
             antibody (PRA) screens to class I and class II antigens for all patients before
             hematopoietic cell transplantation (HCT). If the PRA shows &gt; 10% activity, then flow
             cytometric or B and T cell cytotoxic cross matches should be obtained. The donor
             should be excluded if any of the cytotoxic cross match assays are positive. For those
             patients with an HLA class I allele or class II allele or antigen mismatch or
             haploidentical donors, flow cytometric or B and T cell cytotoxic cross matches should
             be obtained regardless of the PRA results. A positive anti‐donor cytotoxic crossmatch
             is an absolute donor exclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phuong Vo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Phuong Vo</last_name>
    <phone>206-667-2749</phone>
    <email>ptvo@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Vo</last_name>
    </contact>
    <investigator>
      <last_name>Phuong Vo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

